SGLT2 Stands For: Sodium-Glucose Cotransporter-2
SGLT2 is the abbreviation for Sodium-Glucose Cotransporter-2, a protein located in the proximal renal tubule that is responsible for reabsorbing filtered glucose from the urine back into the bloodstream 1, 2, 3.
Mechanism and Location
SGLT2 is a transport protein found specifically in the kidney's proximal tubule that normally reabsorbs approximately 90% of filtered glucose. When this transporter is inhibited by medications (SGLT2 inhibitors), glucose reabsorption is blocked, leading to increased urinary glucose excretion (glycosuria) and subsequent reduction in blood glucose levels 3.
Clinical Relevance
SGLT2 inhibitors work by blocking this cotransporter, which:
- Increases urinary glucose excretion by inhibiting renal reabsorption of filtered glucose
- Reduces the renal threshold for glucose
- Improves β-cell function by reducing glucotoxicity
- Reduces insulin resistance and increases insulin sensitivity 3
These medications have evolved beyond diabetes treatment and are now indicated for chronic kidney disease, heart failure with reduced and preserved ejection fraction, and cardiovascular risk reduction 1, 3, 4.
Important Distinction
While SGLT2 is the primary target in the kidney, there is also SGLT1 (Sodium-Glucose Cotransporter-1), which is found in the intestine and plays a different role in glucose absorption. Most SGLT2 inhibitors are selective for SGLT2 and do not significantly interfere with SGLT1 during therapy 5.